Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupi...
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry
About this item
Full title
Author / Creator
Publisher
Springer
Journal title
Language
English
Formats
Publication information
Publisher
Springer
Subjects
More information
Scope and Contents
Contents
Dupilumab was initially approved in 2017 as the first biologic therapy for atopic dermatitis (AD). We characterized adults with AD initiating dupilumab in a real-world setting in the USA/Canada. PROSE is an ongoing, longitudinal, prospective, observational, multicenter registry of patients with AD initiating dupilumab per country-specific prescribi...
Alternative Titles
Full title
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A707815634
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A707815634
Other Identifiers
ISSN
2193-8210
DOI
10.1007/s13555-022-00742-w
